Biotechnology & Life Sciences Global On demand · 24-48h

Global Live Brucellosis Vaccine Market Strategic Research Report

Global Live Brucellosis Vaccine Market Strategic Research Re…
$3,500 USD
Market Research Reports
Strategic Research Report
Global Live Brucellosis Vaccine Market
$1962025
4.4%CAGR
2032Forecast
Market Research Reports · Global
Market Research Reports Intelligence Series

By Type: Strain RB-51, Strain S19, Strain S2, Strain A19, Strain Rev. I

By Application: Cattle, Sheep, Pig, Others

Regional Forecast: Asia Pacific, Latin America, MEA, Europe, North America

Key Players: CZ Vaccines, MSD, Ceva, Colorado Serum, Tecnovax, Syva, Shchelkovo Biocombinat, Jinyu Baoling, Biovet, CAVAC, VETAL, Indian Immunologicals, Dollvet, Hester Biosciences, Qilu Animal Health, Auleon Biologicals

Region: Global
Formats: PDF, Excel, Word & PowerPoint
Base year: 2025 · forecast to 2032
Length: 141 pages
Market size 2025
$196
Million USD
Forecast CAGR
4.4%
2025-2032
Forecast 2032
$264.9
Projected
区域
5
Asia Pacific · Latin America · MEA · Europe · North America

概述

Scope of the Report

The global Live Brucellosis Vaccine market size is predicted to grow from US$ 196 million in 2025 to US$ 263 million in 2032; it is expected to grow at a CAGR of 4.4% from 2026 to 2032.

Live Brucellosis Vaccine is a kind of vaccine used to prevent brucellosis, which is also known as Malta fever or undulant fever. It is a live attenuated vaccine prepared from weakened strains of Brucella bacteria. The attenuated Brucella strains in the live vaccine still retain certain antigenicity, which can stimulate the body's immune system to produce a relatively strong immune response, inducing the production of specific antibodies and cell-mediated immune responses, thereby providing effective protection for the body to prevent the occurrence of brucellosis. The attenuated strains in the live vaccine can replicate to a limited extent in the body, allowing the body's immune system to be continuously stimulated by antigens, resulting in more long-lasting immunity and extending the duration of immune protection.

Global key Live Brucellosis Vaccine players cover CZ Vaccines, MSD, Ceva, Colorado Serum, Tecnovax, etc.

Key Questions Addressed in this Report

What is the 10-year outlook for the global Live Brucellosis Vaccine market?

What factors are driving Live Brucellosis Vaccine market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Live Brucellosis Vaccine market opportunities vary by end market size?

How does Live Brucellosis Vaccine break out by Type, by Application?

This report presents a comprehensive overview of the global Live Brucellosis Vaccine market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

  • Strain RB-51
  • Strain S19
  • Strain S2
  • Strain A19
  • Strain Rev. I

Segment by Application

  • Cattle
  • Sheep
  • Pig
  • Others

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Live Brucellosis Vaccine market:

  • Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
  • Distributors, channel partners and end users in Cattle, Sheep, Pig evaluating demand and sourcing options
  • Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
  • Government agencies, industry associations and research institutions tracking industry developments and policy impact

Market snapshot

Global Live Brucellosis Vaccine Market Strategic Research Report snapshot, 2025–2032

Source: Market Research Reports
Market size CAGR 4.4%
Regional growth momentum
Market share by segment
Key metrics
Base value
$196
2025
Forecast
$264.9
2032
CAGR
4.4%
2025–2032
区域
5
global
Key companies
CZ VaccinesMSDCevaColorado SerumTecnovaxSyvaShchelkovo BiocombinatJinyu Baoling
© MarketResearchReports.comDisclaimer: The actual data may vary in the final report which undergoes verification check post order confirmation.

Segments covered in this report

By Type
Strain RB-51Strain S19Strain S2Strain A19Strain Rev. I
By Application
CattleSheepPigOthers

Table of contents

Click a chapter to expand
01Executive Summary
02Industry Overview & Forecast
  • 2.1.1 Market Definition and Scope
  • 2.1.2 Market Size and Growth Forecast
  • 2.1.3 Volume Analysis
  • 2.1.4 Segment Outlook by Type
  • 2.1.5 Segment Outlook by Application
  • 2.1.6 Regional Outlook
  • 2.1.7 Structural Developments Shaping the Forecast
  • 2.1.8 Forecast Risks and Sensitivities
03Market Segmentation by Type
  • 3.1 Market Segmentation by Type
  • 3.1.1 Market by Type Overview
  • 3.1.2 Strain RB-51
  • 3.1.3 Strain S19
  • 3.1.4 Strain S2
  • 3.1.5 Strain A19
  • 3.1.6 Strain Rev. I
  • 3.1.7 Volume Analysis
04Market Segmentation by Application
  • 4.1 Market Segmentation by Application
  • 4.1.1 Market by Application Overview
  • 4.1.2 Cattle
  • 4.1.3 Sheep
  • 4.1.4 Pig
  • 4.1.5 Others
  • 4.1.6 Volume Analysis
05Regional Market Forecast
  • Asia Pacific
  • North America
  • Europe
  • Middle East & Africa
  • Latin America
06Country-Level Market Forecast
  • 6.1 Asia Pacific
  • 6.1.1 China
  • 6.1.2 Japan
  • 6.1.3 Korea
  • 6.1.4 Southeast Asia
  • 6.1.5 India
  • 6.1.6 Australia
  • 6.1.7 Rest of Asia Pacific
  • 6.2 North America
  • 6.2.1 United States
  • 6.2.2 Canada
  • 6.2.3 Mexico
  • 6.2.4 Rest of North America
  • 6.3 Europe
  • 6.3.1 Germany
  • 6.3.2 France
  • 6.3.3 UK
  • 6.3.4 Italy
  • 6.3.5 Russia
  • 6.3.6 Rest of Europe
  • 6.4 Middle East & Africa
  • 6.4.1 Egypt
  • 6.4.2 South Africa
  • 6.4.3 Israel
  • 6.4.4 Turkey
  • 6.4.5 GCC Countries
  • 6.4.6 Rest of Middle East & Africa
  • 6.5 Latin America
  • 6.5.1 Brazil
  • 6.5.2 Rest of Latin America
07Growth Drivers & Inhibitors
  • 7.1 Growth Drivers & Inhibitors
  • 7.1.1 Section Overview
  • 7.1.2 Growth Drivers
  • 7.1.3 Growth Inhibitors
  • 7.1.4 Driver and Inhibitor Impact Assessment
  • 7.1.5 Analyst Perspective
08Key Company Profiles
  • 8.1 CZ Vaccines
  • 8.1.1 Company Overview
  • 8.1.2 Key Products & Segments
  • 8.1.3 Financial Performance (2023–2025)
  • 8.1.4 Business Strategy
  • 8.1.5 SWOT Analysis
  • 8.1.6 Strategic Implications (2026–2032)
  • 8.2 MSD
  • 8.2.1 Company Overview
  • 8.2.2 Key Products & Segments
  • 8.2.3 Financial Performance (2023–2025)
  • 8.2.4 Business Strategy
  • 8.2.5 SWOT Analysis
  • 8.2.6 Strategic Implications (2026–2032)
  • 8.3 Ceva
  • 8.3.1 Company Overview
  • 8.3.2 Key Products & Segments
  • 8.3.3 Financial Performance (2023–2025)
  • 8.3.4 Business Strategy
  • 8.3.5 SWOT Analysis
  • 8.3.6 Strategic Implications (2026–2032)
  • 8.4 Colorado Serum
  • 8.4.1 Company Overview
  • 8.4.2 Key Products & Segments
  • 8.4.3 Financial Performance (2023–2025)
  • 8.4.4 Business Strategy
  • 8.4.5 SWOT Analysis
  • 8.4.6 Strategic Implications (2026–2032)
  • 8.5 Tecnovax
  • 8.5.1 Company Overview
  • 8.5.2 Key Products & Segments
  • 8.5.3 Financial Performance (2023–2025)
  • 8.5.4 Business Strategy
  • 8.5.5 SWOT Analysis
  • 8.5.6 Strategic Implications (2026–2032)
  • 8.6 Syva
  • 8.6.1 Company Overview
  • 8.6.2 Key Products & Segments
  • 8.6.3 Financial Performance (2023–2025)
  • 8.6.4 Business Strategy
  • 8.6.5 SWOT Analysis
  • 8.6.6 Strategic Implications (2026–2032)
  • 8.7 Shchelkovo Biocombinat
  • 8.7.1 Company Overview
  • 8.7.2 Key Products & Segments
  • 8.7.3 Financial Performance (2023–2025)
  • 8.7.4 Business Strategy
  • 8.7.5 SWOT Analysis
  • 8.7.6 Strategic Implications (2026–2032)
  • 8.8 Jinyu Baoling
  • 8.8.1 Company Overview
  • 8.8.2 Key Products & Segments
  • 8.8.3 Financial Performance (2023–2025)
  • 8.8.4 Business Strategy
  • 8.8.5 SWOT Analysis
  • 8.8.6 Strategic Implications (2026–2032)
  • 8.9 Biovet
  • 8.9.1 Company Overview
  • 8.9.2 Key Products & Segments
  • 8.9.3 Financial Performance (2023–2025)
  • 8.9.4 Business Strategy
  • 8.9.5 SWOT Analysis
  • 8.9.6 Strategic Implications (2026–2032)
  • 8.10 CAVAC
  • 8.10.1 Company Overview
  • 8.10.2 Key Products & Segments
  • 8.10.3 Financial Performance (2023–2025)
  • 8.10.4 Business Strategy
  • 8.10.5 SWOT Analysis
  • 8.10.6 Strategic Implications (2026–2032)
  • 8.11 VETAL
  • 8.11.1 Company Overview
  • 8.11.2 Key Products & Segments
  • 8.11.3 Financial Performance (2023–2025)
  • 8.11.4 Business Strategy
  • 8.11.5 SWOT Analysis
  • 8.11.6 Strategic Implications (2026–2032)
  • 8.12 Indian Immunologicals
  • 8.12.1 Company Overview
  • 8.12.2 Key Products & Segments
  • 8.12.3 Financial Performance (2023–2025)
  • 8.12.4 Business Strategy
  • 8.12.5 SWOT Analysis
  • 8.12.6 Strategic Implications (2026–2032)
  • 8.13 Dollvet
  • 8.13.1 Company Overview
  • 8.13.2 Key Products & Segments
  • 8.13.3 Financial Performance (2023–2025)
  • 8.13.4 Business Strategy
  • 8.13.5 SWOT Analysis
  • 8.13.6 Strategic Implications (2026–2032)
  • 8.14 Hester Biosciences
  • 8.14.1 Company Overview
  • 8.14.2 Key Products & Segments
  • 8.14.3 Financial Performance (2023–2025)
  • 8.14.4 Business Strategy
  • 8.14.5 SWOT Analysis
  • 8.14.6 Strategic Implications (2026–2032)
  • 8.15 Qilu Animal Health
  • 8.15.1 Company Overview
  • 8.15.2 Key Products & Segments
  • 8.15.3 Financial Performance (2023–2025)
  • 8.15.4 Business Strategy
  • 8.15.5 SWOT Analysis
  • 8.15.6 Strategic Implications (2026–2032)
  • 8.16 Auleon Biologicals
  • 8.16.1 Company Overview
  • 8.16.2 Key Products & Segments
  • 8.16.3 Financial Performance (2023–2025)
  • 8.16.4 Business Strategy
  • 8.16.5 SWOT Analysis
  • 8.16.6 Strategic Implications (2026–2032)
09Competitive Landscape
  • 9.1 Competitive Landscape Overview
  • 9.2 Competitive Intensity Assessment
  • 9.3 Key Player Strategies & Positioning
  • 9.4 Competitive Dynamics & Strategic Outlook
  • 9.4.1 Emerging Competitive Threats
  • 9.4.2 Consolidation vs. Fragmentation Outlook
  • 9.4.3 Competitive Response Matrix
  • 9.4.4 Strategic Recommendations, 2026–2032
10Porter's Five Forces Analysis
  • 10.1 Threat of New Entrants
  • 10.2 Bargaining Power of Buyers
  • 10.3 Bargaining Power of Suppliers
  • 10.4 Threat of Substitutes
  • 10.5 Competitive Rivalry
11PESTLE Analysis
  • 11.1 Political
  • 11.2 Economic
  • 11.3 Social and Demographic
  • 11.4 Technological
  • 11.5 Legal and Regulatory
  • 11.6 Environmental
  • 11.7 Strategic Implications of the PESTLE Assessment
12SWOT Analysis
13Future Trends & Outlook
  • 13.1 Future Trends & Outlook
  • 13.1.1 Trend Summary and Commercial Maturity Assessment
  • 13.1.2 Technology and Innovation Trends
  • 13.1.3 Long-Term Market Outlook
  • 13.1.4 Investment & M&A Activity Outlook
  • 13.1.5 Overall Outlook Assessment

Frequently asked questions

What is the size of the global Live Brucellosis Vaccine market?
The global Live Brucellosis Vaccine market is estimated at US$ 196 million in 2025 (base year) and is projected to reach US$ 263 million by 2032.
What is the forecast CAGR for the Live Brucellosis Vaccine market?
The market is expected to grow at a CAGR of 4.4% from 2026 to 2032, expanding from US$ 196 million in 2025 to US$ 263 million in 2032, roughly 1.3 times its base-year value.
What is Live Brucellosis Vaccine?
Live Brucellosis Vaccine is a kind of vaccine used to prevent brucellosis, which is also known as Malta fever or undulant fever. It is a live attenuated vaccine prepared from weakened strains of Brucella bacteria.
What are the main segments of the Live Brucellosis Vaccine market by type?
By type, the market is segmented into Strain RB-51, Strain S19, Strain S2, Strain A19 and Strain Rev. I.
Which applications drive demand in the Live Brucellosis Vaccine market?
Key applications covered include Cattle, Sheep, Pig and Others.
Who are the key players in the Live Brucellosis Vaccine market?
Key players profiled include CZ Vaccines, MSD, Ceva, Colorado Serum, Tecnovax, Syva, Shchelkovo Biocombinat and Jinyu Baoling, among 16 companies covered in total.
Which regions and countries are covered for Live Brucellosis Vaccine?
The market is analysed across Asia Pacific, North America, Europe, Middle East & Africa and Latin America, with 20 country-level markets including China, Japan, United States, Canada, Germany, France, Egypt and South Africa.
What is driving growth in the Live Brucellosis Vaccine market?
What factors are driving Live Brucellosis Vaccine market growth, globally and by region?
Who should buy the Live Brucellosis Vaccine market report?
The report is intended for manufacturers and solution providers, distributors and end users in Cattle, Sheep and Pig, investors and consultants, and government or industry bodies who need market size, segmentation, competitive and regional data for the Live Brucellosis Vaccine market.
What license options are available for this report?
The report is available as a Single User License (US$ 3,500, one named user), a Site License (US$ 5,250, up to 10 users) and a Global / Corporate License (US$ 7,000, unlimited users), all delivered in PDF format.

Research Methodology

All MarketResearchReports.com strategic research reports follow a rigorous, multi-stage methodology combining AI-assisted data synthesis with expert analyst validation.

01
Secondary Research & Data Aggregation

Systematic collection from 500+ verified sources including SEC filings, industry databases (Bloomberg, Statista, OECD), regulatory filings, trade publications, patent databases, and company annual reports. AI-assisted extraction identifies relevant data points across 10,000+ documents per report.

02
Market Sizing — Bottom-Up & Top-Down

Dual-validation approach: bottom-up sizing aggregates segment-level production, consumption, and trade data; top-down sizing cross-validates against macroeconomic indicators and total addressable market estimates. Discrepancies >5% trigger analyst review.

03
Competitive Intelligence

Company profiles built from public financial disclosures, product launches, M&A activity, job postings (as capability proxies), and supply chain mapping. Market share estimates triangulated across revenue, capacity, and shipment data.

04
Demand Forecasting

CAGR projections use time-series regression on 5-10 years of historical data, adjusted for identified demand drivers (technology adoption curves, regulatory catalysts, demographic shifts) and demand inhibitors (cost barriers, substitution risk). Scenario modeling covers base, optimistic, and conservative cases.

05
Analyst Validation & Quality Assurance

All quantitative outputs reviewed by a domain-specialist analyst before publication. Data triangulation requires minimum 3 independent sources for every key figure. Reports undergo a structured peer review against our 47-point quality checklist covering methodology, data citations, logical consistency, and formatting standards.

06
Continuous Updates

On-demand reports are generated at time of purchase, incorporating the most recent available data. Static reports are republished when underlying market conditions shift by >10% from baseline assumptions. Purchasers receive update notifications for 12 months.

All data sources are cited within the report. View our full research methodology →
Select a license
from US$3,500.00
Report License Type
Optional add-ons
On demand · delivered within 24-48 hours
Secure checkout · SSL encrypted
License terms included
Post-purchase analyst support
Custom research

Need a customized version?

Get country-, segment- or company-specific intelligence tailored to your exact requirements.

Request custom research →
Talk to a research advisor USA: +1-302-703-9904 India: +91-8762746600
Trusted by

Leading Brands in This Industry

Logos are trademarks of their respective owners and indicate a verified past business relationship, not a current partnership or endorsement.